Fully Automated High-Plex Proteomics to Enable Accelerated Immune Medicine
Jen Chen and Sean Mackay discuss how high-plex automated immunoassays can accelerate the development of advanced therapeutics
Today's Clinical Lab
Today’s Clinical Lab is a reader-centric publication that keeps clinical professionals up to date with today’s rapidly changing lab industry with in-depth and timely editorial content and resources, including clinical industry news and insights into the latest trends, technologies, and techniques in the clinical lab.
Fully Automated High-Plex Proteomics to Enable Accelerated Immune Medicine
IsoPlexis’ new high-plex automated immunoassay applications uniquely enable the decentralization of multiplexed and fully automated functional proteomics for accelerated insights.
This technology can identify 20-30 cytokines in bulk, with only 11 µL of sample per chip, analyzed on the fully automated, benchtop IsoLight system.
IsoPlexis’ proteomics platform widens access to advanced insights provided by improved and reengineered ELISA technology, with a small footprint and end-to-end automation. Recently, high-plex automated immunoassays were used in multiple high-impact studies, characterizing inflammatory markers of neurological symptoms of COVID-19 (BMC Neurology & Cell), and in discovering metastasis initiators to develop a potential therapy to improve cancer patient outcomes.
In this webinar brought to you by IsoPlexis, Jon Chen and Sean Mackay will discuss how high-plex automated immunoassays facilitate critical discoveries in immune medicine, accelerating the development of advanced therapeutics across disciplines such as cellular regenerative medicine, cancer immunology, infectious disease, and inflammation.
We’ve updated our Privacy Policy to make it clearer how we use your personal data. Please read our Cookie Policy to learn how we use cookies to provide you with a better experience.
